CPT® Code 80230

The CPT® Code 80230 refers to a laboratory test specifically designed to monitor therapeutic drug levels of infliximab. Infliximab is a chimeric monoclonal antibody that combines human and murine elements, targeting a critical immune system protein known as tumor necrosis factor alpha (TNFa). This medication is primarily utilized in the treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, and it may also be indicated for inflammatory arthritis. The mechanism of action of infliximab involves its anti-inflammatory properties, which can lead to a significant immune response characterized by the formation of antibodies against TNFa. This immune response can result in a reduction of serum drug levels, potentially diminishing the therapeutic efficacy of infliximab. It is important to note that a subset of patients may experience inadequate therapeutic response due to low serum trough concentrations of infliximab. This phenomenon is categorized into two groups: primary non-responders, who do not respond adequately during the initial induction phase of treatment, and secondary non-responders, who initially show improvement but later lose their response over time. The rates of these non-responses can be significant, with 10-30% of patients classified as primary non-responders and an additional 50% as secondary non-responders. To address these challenges, the rapid point-of-care test for semi-quantitative levels of infliximab is employed, allowing clinicians to monitor serum drug trough concentrations just before the next scheduled dose. This timely monitoring enables healthcare providers to make necessary adjustments to the treatment regimen without delaying the dosing schedule. The testing process involves obtaining a blood sample through a separately reported procedure, followed by diluting the serum with a buffering agent, mixing it, and loading it into a test cartridge. The cartridge is then placed into a preprogrammed reading device provided by the manufacturer, where it undergoes a 15-minute incubation period. The results of the test are subsequently displayed on a digital screen, providing immediate feedback on the patient's infliximab levels.